Security Snapshot

TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) Institutional Ownership

CUSIP: 88338N206

13F Institutional Holders and Ownership History from Q4 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

23

Shares (Excl. Options)

3.13MFull value: 3,126,903 · shares · 30 Sep 2026

Price

$2.03

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+60,928
Value change
+$123,677
Number of holders
23
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
11,627,985
SEC-reported price per share
$1.96
Insider filing price
$1.96
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 88338N206.
  • 23 institutions reported positions in Q3 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 43 to 23 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $8.1MFull value: $8,101,664 · USD · 30 Jun 2026
    to
    $6.35MFull value: $6,347,672 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 23 institutions filings for Q3 2026.

Open SEC evidence

Security key

88338N206

13F reference period

Q3 2026

13F holders

23

13D/G owners

2

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
2
Security
TXMD
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Baselake Partners, LP 6.8% +32% $1,668,383 +$387,231 790,703 +30% Baselake Partners, LP 30 Jun 2026
Clearline Capital LP 5.5% $705,096 635,222 Clearline Capital LP 31 Dec 2024
As of 30 Sep 2026, 23 institutional investors reported holding
3.13MFull value: 3,126,903 · shares · 30 Sep 2026
shares of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD). This represents 27% of the company’s total
11.63MFull value: 11,627,985 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 21 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
26%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 10% 1,192,191 0.02% $2,420,148
Clearline Capital LP 5.5% 635,222 0.08% $1,289,501
VANGUARD CAPITAL MANAGEMENT LLC 3.4% 394,397 0% $800,626
Tejara Capital Ltd 2.8% 327,282 0.32% $664,382
RENAISSANCE TECHNOLOGIES LLC 1.2% 142,199 0% $288,664
GEODE CAPITAL MANAGEMENT, LLC 0.92% 106,851 0% $216,966
VANGUARD FIDUCIARY TRUST CO 0.55% 63,831 0% $129,577
STATE STREET CORP 0.26% 30,100 0% $61,103
DIMENSIONAL FUND ADVISORS LP 0.21% 23,922 0% $48,562
Empowered Funds, LLC 0.14% 16,705 0% $33,911
Ashton Thomas Private Wealth, LLC 0.14% 16,581 0% $33,659
US BANCORP \DE\ 0.13% 14,740 0% $29,922
XTX Topco Ltd 0.09% 10,683 0% $21,686
Vanguard Global Advisers, LLC 0.04% 4,937 0% $10,022
SBI Securities Co., Ltd. 0.01% 1,263 0% $2,564
Activest Wealth Management 0% 40 0% $81
Farther Finance Advisors, LLC 0% 30 0% $61
IFP Advisors, Inc 0% 21 0% $43
GK Wealth Management LLC 0% 1 0% $2
HOLLENCREST CAPITAL MANAGEMENT 0% 1 0% $2
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.1% 11,800 0% $23,954

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
20
Headline period
Q3 2026
Rows shown
1-20 of 20
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 3,126,903 $6,347,672 +$123,677 $2.03 23
2026 Q2 3,666,310 $8,101,664 -$498,589 $2.21 43
2026 Q1 3,930,452 $7,939,211 +$1,050,571 $2.02 47
2025 Q4 3,384,889 $5,517,397 +$146,413 $1.63 41
2025 Q3 3,303,788 $3,542,705 +$51,253 $1.08 43
2025 Q2 3,255,627 $3,776,528 -$96,760 $1.16 39
2025 Q1 3,343,589 $3,092,849 -$161,728 $0.92 39
2024 Q4 3,528,745 $3,034,778 +$127,744 $0.86 38
2024 Q3 3,379,026 $5,609,223 -$32,659 $1.66 34
2024 Q2 3,408,566 $5,487,879 -$167 $1.61 34
2024 Q1 3,377,053 $7,732,812 +$286,534 $2.29 43
2023 Q4 3,251,877 $7,316,577 -$358,133 $2.25 36
2023 Q3 2,987,555 $9,324,433 +$112,168 $3.02 36
2023 Q2 3,031,054 $12,488,021 -$296,992 $4.12 40
2023 Q1 3,115,140 $11,682,289 -$1,635,363 $3.75 38
2022 Q4 3,475,915 $19,431,091 +$6,039,029 $5.59 43
2022 Q3 2,070,807 $13,750,198 -$489,469 $6.64 29
2022 Q2 1,993,507 $19,835,726 +$19,831,622 $9.95 36
2022 Q1 10,800 $4,104 +$304 $0.38 2
2021 Q4 10,000 $3,555 $0.36 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .